Table 4.
n | COVID-19 | n | Control | p value | |
---|---|---|---|---|---|
CT (s), median (IQR) | 21 | 103.0 (95.0–119.2) | 14 | 91.0 (83.5–100.4) | 0.035 |
CFT (s), median (IQR) | 21 | 64.0 (56.2–73.0) | 14 | 78.0 (67.5–89.0) | 0.047 |
α, median (IQR) | 21 | 77.0 (75.0–81.0) | 14 | 74.5 (72.7–77.2) | 0.027 |
MCF, median (IQR) | 21 | 68.0 (64.0–72.5) | 14 | 63.5 (60.7–67.7) | 0.035 |
ML (%), median (IQR) | 21 | 14 (10–45.5) | 14 | 36.5 (13.5–56.7) | 0.092 |
LI30 (%), median (IQR) | 21 | 99.0 (80.5–100.0) | 14 | 96.0 (82.7–100.0) | 0.931 |
CT coagulation time, CFT clot formation time, α alpha angle, MCF maximum clot firmness, ML maximum lysis, LI30 lysis index 30 min after CT, IQR interquartile range